2022-06-300001828253--12-312022Q2錯誤00018282532022-01-012022-06-300001828253EibLoanAgreement：EibLoanGonement.TrancheOneMember2022-02-172022-02-170001828253EVAX：ExecutiveManagement協議成員2022-08-020001828253IFRS-FULL：普通共享成員2022-06-300001828253IFRS-FULL：普通共享成員2021-12-310001828253VAX：保證書成員2021-12-310001828253VAX：保證書成員2020-12-310001828253VAX：保證書成員2022-06-300001828253VAX：保證書成員2021-06-300001828253VAX：保證書成員SRT：首席運營官成員2022-01-012022-06-300001828253VAX：保證書成員SRT：首席財務官成員2022-01-012022-06-300001828253VAX：保證書成員2021-01-012021-06-300001828253VAX：EibLoanGonement.TrancheTwoMember2020-08-310001828253VAX：EibLoanGonement.TrancheThreeMember2020-08-310001828253EibLoanAgreement：EibLoanGonement.TrancheOneMember2020-08-310001828253IFRS-FULL：擔保預留成員2022-06-300001828253IFRS-FULL：擔保預留成員2021-12-310001828253VAX：EibLoanaccesementMember2022-04-012022-06-300001828253IFRS-Full：SharePremiumMembers2022-04-012022-06-300001828253IFRS-Full：RetainedEarningsMembers2022-04-012022-06-300001828253Ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-04-012022-06-300001828253IFRS-Full：IssuedCapitalMembers2022-04-012022-06-300001828253IFRS-Full：SharePremiumMembers2022-01-012022-03-310001828253IFRS-Full：RetainedEarningsMembers2022-01-012022-03-310001828253Ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-01-012022-03-310001828253IFRS-Full：IssuedCapitalMembers2022-01-012022-03-3100018282532022-01-012022-03-310001828253IFRS-Full：SharePremiumMembers2021-04-012021-06-300001828253IFRS-Full：RetainedEarningsMembers2021-04-012021-06-300001828253IFRS-Full：IssuedCapitalMembers2021-04-012021-06-300001828253IFRS-Full：SharePremiumMembers2021-01-012021-03-310001828253IFRS-Full：RetainedEarningsMembers2021-01-012021-03-310001828253IFRS-Full：IssuedCapitalMembers2021-01-012021-03-310001828253IFRS-Full：IssuedCapitalMembers2022-06-142022-06-140001828253IFRS-Full：IssuedCapitalMembers2022-06-082022-06-080001828253IFRS-Full：IssuedCapitalMembers2022-06-072022-06-070001828253IFRS-Full：IssuedCapitalMembers2022-04-202022-04-200001828253IFRS-FULL：普通共享成員2022-01-012022-06-300001828253Ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-04-012021-06-300001828253Ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-03-3100018282532021-01-012021-03-310001828253IFRS-Full：SharePremiumMembers2022-06-300001828253IFRS-Full：RetainedEarningsMembers2022-06-300001828253Ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-06-300001828253IFRS-Full：IssuedCapitalMembers2022-06-300001828253IFRS-Full：SharePremiumMembers2022-03-310001828253IFRS-Full：RetainedEarningsMembers2022-03-310001828253Ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-03-310001828253IFRS-Full：IssuedCapitalMembers2022-03-3100018282532022-03-310001828253IFRS-Full：SharePremiumMembers2021-12-310001828253IFRS-Full：RetainedEarningsMembers2021-12-310001828253Ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-12-310001828253IFRS-Full：IssuedCapitalMembers2021-12-310001828253IFRS-Full：SharePremiumMembers2021-06-300001828253IFRS-Full：RetainedEarningsMembers2021-06-300001828253Ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-06-300001828253IFRS-Full：IssuedCapitalMembers2021-06-300001828253IFRS-Full：SharePremiumMembers2021-03-310001828253IFRS-Full：RetainedEarningsMembers2021-03-310001828253Ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-03-310001828253IFRS-Full：IssuedCapitalMembers2021-03-3100018282532021-03-310001828253IFRS-Full：SharePremiumMembers2020-12-310001828253IFRS-Full：RetainedEarningsMembers2020-12-310001828253Ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001828253IFRS-Full：IssuedCapitalMembers2020-12-310001828253IFRS-Full：IssuedCapitalMembers2022-01-012022-06-3000018282532021-06-3000018282532020-12-310001828253VAX：EibLoanaccesementMember2022-06-300001828253EVAX：DtuScience公園金融成員2022-06-300001828253EibLoanAgreement：EibLoanGonement.TrancheOneMember2022-02-170001828253EVAX：DtuScience公園金融成員2021-12-310001828253EVAX：DtuScience公園金融成員2020-10-3100018282532022-04-012022-06-3000018282532021-04-012021-06-300001828253IFRS-Full：TopOfRangeMemberVAX：保證書成員2022-01-012022-06-300001828253IFRS-FULL：底部範圍成員VAX：保證書成員2022-01-012022-06-3000018282532022-06-072022-06-0700018282532022-06-070001828253IFRS-Full：TopOfRangeMember2022-06-070001828253IFRS-FULL：底部範圍成員2022-06-0700018282532021-01-012021-06-300001828253IFRS-FULL：普通共享成員EVAX：StockSplitMember2021-01-040001828253IFRS-FULL：普通共享成員2022-06-142022-06-140001828253IFRS-FULL：普通共享成員2022-06-082022-06-080001828253IFRS-FULL：普通共享成員2022-06-072022-06-070001828253IFRS-FULL：普通共享成員2022-04-202022-04-200001828253EVAX：American DepositarySharesMemberEvax:SellingShareholderRegistrationStatementMember2022-07-070001828253VAX：EibLoanaccesementMember2022-01-012022-06-300001828253VAX：EibLoanaccesementMember2020-08-310001828253VAX：EibLoanaccesementMember2022-02-170001828253VAX：OfficeSpaceMember2020-10-310001828253VAX：實驗室空間成員2020-10-3100018282532020-10-310001828253IFRS-FULL：普通共享成員EVAX：StockSplitMemberVAX：保證書成員2021-01-042021-01-040001828253VAX：保證書成員2022-01-012022-06-300001828253EVAX：DtuScience公園金融成員2020-10-012020-10-310001828253VAX：EibLoanaccesementMember2020-08-012020-08-310001828253EAX：EibWarrantsMembers2022-02-172022-02-1700018282532021-12-310001828253EVAX：ExecutiveManagement協議成員2022-08-022022-08-0200018282532022-06-300001828253VAX：EibLoanaccesementMember2022-02-172022-02-170001828253EAX：EibWarrantsMembers2022-02-170001828253IFRS-FULL：擔保預留成員2022-01-012022-06-300001828253EVAX：American DepositarySharesMemberEvax:SellingShareholderRegistrationStatementMember2022-07-072022-07-07ISO4217：DKKISO 4217：美元ISO4217：DKKXbrli：共享Xbrli：共享Xbrli：純Utr：SqmEVAX：部分ISO 4217：美元Xbrli：共享ISO4217：歐元

美國

美國證券交易委員會

華盛頓特區，20549

表格6-K

外國私人發行人報告

依據第13a-16或15d-16條

根據1934年的《證券交易法》

2022年8月

委託公文編號：001-39950

Evaxion Biotech A/S

(註冊人的確切姓名載於其章程)

Neergaards Vej博士5f

DK-2970HERSHOLM

丹麥

(主要執行辦公室地址)

用複選標記表示註冊人是否在20-F或40-F表格的封面下提交或將提交年度報告。

Form 20-F ☒Form 40-F ☐

用複選標記表示註冊人是否按照S-T規則第101(B)(1)條所允許的紙質形式提交表格6-K：☐

用複選標記表示註冊人是否按照S-T規則第101(B)(7)條所允許的紙質形式提交表格6-K：☐

以引用方式成立為法團

本報告中表格6-K的證物99.1和99.2應被視為已通過引用納入Evaxion Biotech A/S(“本公司”)的表格S-8(註冊號333-255064)和表格F-3(註冊號333-265132)的註冊説明書(包括構成該等註冊説明書一部分的任何招股説明書)，並自提交本報告之日起成為註冊説明書的一部分，但不得被隨後提交或提交的文件或報告所取代。

在本報告的6-K表格中，提供了關於該公司截至2022年6月30日的財政季度的財務結果的信息。

陳列品


展品
不是的。		描述
99.1		未經審計的簡明合併中期財務報表。
99.2		管理層對財務狀況和經營結果的討論和分析。

簽名

根據修訂後的1934年《證券交易法》的要求，註冊人已正式促使本報告由正式授權的簽署人代表其簽署。


	Evaxion Biotech A/S

日期：2022年8月11日	發信人：	/s/Bo Karmark
		博·卡爾馬克
		首席財務官